MARKET

SNGX

SNGX

Soligenix Inc
NASDAQ
1.630
+0.080
+5.16%
After Hours: 1.639 +0.009 +0.55% 18:33 12/04 EST
OPEN
1.540
PREV CLOSE
1.550
HIGH
1.670
LOW
1.510
VOLUME
241.46K
TURNOVER
--
52 WEEK HIGH
6.23
52 WEEK LOW
1.090
MARKET CAP
16.44M
P/E (TTM)
-0.4454
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at SNGX last week (1124-1128)?
Weekly Report · 3d ago
Soligenix Inc. unveils pipeline progress and rare disease treatment strategies in new corporate presentation
Reuters · 11/24 17:52
Weekly Report: what happened at SNGX last week (1117-1121)?
Weekly Report · 11/24 09:15
Soligenix completes enrollment of patients for Phase 3 study evaluating HyBryte
TipRanks · 11/19 12:35
Soligenix Completes Planned Enrollment Of 50 Patients Necessary For Interim Analysis In 80 Patient Confirmatory Phase 3 Double-Blind, Placebo-Controlled Study Evaluating HyBryte In CTCL Treatment
Benzinga · 11/19 12:33
Soligenix Reaches Interim Enrollment Milestone in Phase 3 HyBryte Trial for CTCL
Reuters · 11/19 12:30
SOLIGENIX ACHIEVES ENROLLMENT MILESTONE FOR PLANNED INTERIM ANALYSIS IN CONFIRMATORY PHASE 3 CLINICAL TRIAL OF HYBRYTE™ FOR THE TREATMENT OF CUTANEOUS T-CELL LYMPHOMA
Reuters · 11/19 12:30
Soligenix Regains Nasdaq Compliance as of November 2025
TipRanks · 11/18 21:38
More
About SNGX
Soligenix, Inc. is a late-stage biopharmaceutical company, which is focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. The Company’s segments include Specialized Biotherapeutics, and Public Health Solutions. Its Specialized BioTherapeutics business segment is engaged in developing and focused on the commercialization of HyBryte (a proposed name of SGX301), a novel photodynamic therapy (PDT), utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). Its Public Health Solutions segment includes development programs for RiVax, its ricin toxin vaccine candidate and SGX943, its therapeutic candidate for antibiotic-resistant and emerging infectious diseases and its vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax, its vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2).

Webull offers Soligenix Inc stock information, including NASDAQ: SNGX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SNGX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SNGX stock methods without spending real money on the virtual paper trading platform.